Literature DB >> 18204977

Gephyrin alterations due to protein accumulation stress are reduced by the lysosomal modulator Z-Phe-Ala-diazomethylketone.

Sophia Ryzhikov1, Ben A Bahr.   

Abstract

Inhibitory neurotransmission is important for brain function and requires specific transmitter receptors that are organized in synaptic domains. Gephyrin is a cytoskeletal organization protein that binds tubulin and plays an important role in clustering and organizing select inhibitory neurotransmitter receptors. Here, we tested if gephyrin is altered by protein accumulation stress that is common in age-related neurodegenerative disorders. For this, we used the hippocampal slice model that has been shown to exhibit chloroquine (CQN)-induced protein accumulation, microtubule destabilization, transport failure, and declines in excitatory neurotransmitter receptors and their responses. In addition to the decreases in excitatory receptor subunits and other glutamatergic markers, we found that gephyrin isoforms were reduced across the CQN treatment period. Associated with this decline in gephyrin levels was the production of three gephyrin breakdown products (GBDPs) of 30, 38, and 48 kDa. The induced effects on gephyrin were tested for evidence of recovery through enhancement of lysosomal function that is known to promote protein clearance and microtubule integrity. Using the lysosomal modulator Z-Phe-Ala-diazomethylketone (PADK), gephyrin levels were completely restored in correspondence with the recovery of excitatory glutamatergic components. In addition, GBDPs were significantly reduced after the 2-day PADK treatment, to levels that were at or below those measured in control cultures. These findings suggest that receptor-clustering mechanisms for inhibitory synapses are compromised during protein accumulation events. They also indicate that a lysosomal enhancement strategy can protect gephyrin integrity, which may be vital for the balance between inhibitory and excitatory signaling during age-related diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18204977     DOI: 10.1007/s12031-007-9009-7

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  65 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Widespread expression of gephyrin, a putative glycine receptor-tubulin linker protein, in rat brain.

Authors:  J Kirsch; H Betz
Journal:  Brain Res       Date:  1993-09-10       Impact factor: 3.252

Review 3.  Long-term hippocampal slices: a model system for investigating synaptic mechanisms and pathologic processes.

Authors:  B A Bahr
Journal:  J Neurosci Res       Date:  1995-10-15       Impact factor: 4.164

4.  Age-related decline of presumptive inhibitory synapses in the sensorimotor cortex as revealed by the physical disector.

Authors:  B H Poe; C Linville; J Brunso-Bechtold
Journal:  J Comp Neurol       Date:  2001-10-08       Impact factor: 3.215

5.  Regional synaptic pathology in Alzheimer's disease.

Authors:  W G Honer; D W Dickson; J Gleeson; P Davies
Journal:  Neurobiol Aging       Date:  1992 May-Jun       Impact factor: 4.673

6.  Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity.

Authors:  David A Karanian; Queenie B Brown; Alexandros Makriyannis; Therese A Kosten; Ben A Bahr
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

7.  Cytoskeletal changes in rat cortical neurons induced by long-term intraventricular infusion of leupeptin.

Authors:  S Takauchi; K Miyoshi
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

8.  Delayed protection by MK-801 and tetrodotoxin in a rat organotypic hippocampal culture model of ischemia.

Authors:  J J Vornov; R C Tasker; J T Coyle
Journal:  Stroke       Date:  1994-02       Impact factor: 7.914

Review 9.  A focus on the synapse for neuroprotection in Alzheimer disease and other dementias.

Authors:  Paul Coleman; Howard Federoff; Roger Kurlan
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

Review 10.  Molecular mechanisms that underlie structural and functional changes at the postsynaptic membrane during synaptic plasticity.

Authors:  H V Wheal; Y Chen; J Mitchell; M Schachner; W Maerz; H Wieland; D Van Rossum; J Kirsch
Journal:  Prog Neurobiol       Date:  1998-08       Impact factor: 11.685

View more
  8 in total

1.  Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.

Authors:  Vinogran Naidoo; David A Karanian; Subramanian K Vadivel; Johnathan R Locklear; JodiAnne T Wood; Mahmoud Nasr; Pamela Marie P Quizon; Emily E Graves; Vidyanand Shukla; Alexandros Makriyannis; Ben A Bahr
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

2.  Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseases.

Authors:  Ben A Bahr; Meagan L Wisniewski; David Butler
Journal:  Rejuvenation Res       Date:  2012-04       Impact factor: 4.663

3.  Potential Alzheimer's Disease Therapeutics Among Weak Cysteine Protease Inhibitors Exhibit Mechanistic Differences Regarding Extent of Cathepsin B Up-Regulation and Ability to Block Calpain.

Authors:  Heather Romine; Katherine M Rentschler; Kaitlan Smith; Ayanna Edwards; Camille Colvin; Karen Farizatto; Morgan C Pait; David Butler; Ben A Bahr
Journal:  Eur Sci J       Date:  2017-10

4.  Nonpeptidic lysosomal modulators derived from z-phe-ala-diazomethylketone for treating protein accumulation diseases.

Authors:  Kishore Viswanathan; Dennis J Hoover; Jeannie Hwang; Meagan L Wisniewski; Uzoma S Ikonne; Ben A Bahr; Dennis L Wright
Journal:  ACS Med Chem Lett       Date:  2012-09-09       Impact factor: 4.345

5.  A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity.

Authors:  Vinogran Naidoo; Spyros P Nikas; David A Karanian; Jeannie Hwang; Jianhong Zhao; JodiAnne T Wood; Shakiru O Alapafuja; Subramanian K Vadivel; David Butler; Alexandros Makriyannis; Ben A Bahr
Journal:  J Mol Neurosci       Date:  2010-11-11       Impact factor: 3.444

6.  Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models.

Authors:  David Butler; Jeannie Hwang; Candice Estick; Akiko Nishiyama; Saranya Santhosh Kumar; Clive Baveghems; Hollie B Young-Oxendine; Meagan L Wisniewski; Ana Charalambides; Ben A Bahr
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

7.  Aβ42-mediated proteasome inhibition and associated tau pathology in hippocampus are governed by a lysosomal response involving cathepsin B: Evidence for protective crosstalk between protein clearance pathways.

Authors:  Karen L G Farizatto; Uzoma S Ikonne; Michael F Almeida; Merari F R Ferrari; Ben A Bahr
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

8.  The Role of Lysosomes in a Broad Disease-Modifying Approach Evaluated across Transgenic Mouse Models of Alzheimer's Disease and Parkinson's Disease and Models of Mild Cognitive Impairment.

Authors:  Jeannie Hwang; Candice M Estick; Uzoma S Ikonne; David Butler; Morgan C Pait; Lyndsie H Elliott; Sarah Ruiz; Kaitlan Smith; Katherine M Rentschler; Cary Mundell; Michael F Almeida; Nicole Stumbling Bear; James P Locklear; Yara Abumohsen; Cecily M Ivey; Karen L G Farizatto; Ben A Bahr
Journal:  Int J Mol Sci       Date:  2019-09-09       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.